Andra AP fonden Reduces Stock Position in Gilead Sciences, Inc. $GILD

Andra AP fonden lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.2% during the 4th quarter, HoldingsChannel reports. The firm owned 482,800 shares of the biopharmaceutical company’s stock after selling 114,700 shares during the period. Gilead Sciences comprises 0.7% of Andra AP fonden’s holdings, making the stock its 24th largest position. Andra AP fonden’s holdings in Gilead Sciences were worth $59,259,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ares Financial Consulting LLC purchased a new stake in Gilead Sciences in the fourth quarter worth approximately $28,000. Financial Consulate Inc. boosted its holdings in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its holdings in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Godfrey Financial Associates Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth approximately $34,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. Leerink Partners dropped their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Gilead Sciences in a report on Tuesday. Mizuho raised their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Argus lifted their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $156.93.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,000 shares of company stock worth $9,047,570 in the last three months. Company insiders own 0.30% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Bernstein initiated/maintained a Buy view on Gilead, adding to the bullish analyst sentiment around the stock. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), which strengthens the company’s growth story and HIV franchise outlook. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Gilead’s HIV business continues to get attention for momentum from Biktarvy, Descovy, and Yeztugo, with late-stage pipeline progress supporting the long-term earnings outlook. Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
• Positive Sentiment: Recent Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis also reinforced confidence in Gilead’s pipeline development. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
• Neutral Sentiment: Gilead was cited in broader articles about pharma/biotech M&A and healthcare investing, which may keep the stock on traders’ radar but does not directly change fundamentals. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
• Neutral Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside, though it is not a fundamental development.
• Neutral Sentiment: Gilead Foundation’s ~$3 million HIV/AIDS education commitment is positive for brand and ESG perception, but the financial impact is likely limited. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead Sciences Trading Up 3.6%

Shares of Gilead Sciences stock opened at $125.87 on Friday. The company’s fifty day simple moving average is $133.46 and its 200-day simple moving average is $134.34. The stock has a market capitalization of $156.28 billion, a PE ratio of 17.15 and a beta of 0.31. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.